All-cause mortality in statin-associated immune-mediated necrotizing myopathy compared with idiopathic inflammatory myopathy.

Authors

Oluoma M Edeh, Tam N Dinh, Maheswari Muruganandam, Frank X O'Sullivan, Avinash Sahu, Wilmer L Sibbitt

Published in

Rheumatology (Oxford, England). Sep 24, 2026. Epub Sep 24, 2026.

Abstract

Statin-associated immune-mediated necrotizing myopathy (IMNM) is a distinct idiopathic inflammatory myopathy (IIM) associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibodies. The present study determined all-cause mortality among patients with statin-associated IMNM.
In this retrospective cohort study of 142 adult patients with IIM evaluated at a tertiary academic medical center, statin-associated IMNM was defined by IMNM with recent statin exposure. IIM was defined by standard criteria. The primary outcome was all-cause mortality. Age-adjusted Cox proportional hazards models were the primary analyses with additional adjustments for age, diabetes mellitus, and hyperlipidemia with propensity score-weighted Cox models.
Among 142 patients with IIM, 41 were statin-associated IMNM who were older and had shorter disease duration (p < 0.05). All-cause mortality was higher in statin-associated IMNM (31.7%, 13/41) than in IIM (23.8%, 24/101) (unadjusted HR 2.55, 95% CI 1.24-5.24; p = 0.011), with cardiopulmonary events and infections the major causes of death. In unadjusted analysis, statin-associated IMNM was associated with higher mortality (hazard ratio [HR] 2.55, 95% CI 1.24-5.24) and attenuated after age adjustment (HR 1.98, 95% CI 0.97-4.03) and was no longer statistically significant after adjustment for diabetes and hyperlipidemia (HR 1.70, 95% CI 0.71-4.08). Joint stratification by anti-HMGCR status and age (cutoff 60 years) demonstrated that older patients with statin-associated IMNM had the lowest survival among the four strata (log-rank P = 0.036).
Statin-associated IMNM is associated with higher mortality than other myositis subtypes; this excess attenuates after adjustment for age and cardiometabolic comorbidity, indicating these pre-existing conditions identify a higher-risk clinical phenotype.

PMID:
42786572
Bibliographic data and abstract were imported from PubMed on 25 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.